402 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 tecan (PETACC 3-EORTC 40993-SAKK 60/00 trial) [abstract 4001]. J Clin Oncol 2009;27(15 suppl):169s. Sinicrope FA, Sargent DJ. Clinical implications of microsatellite instabil- ity in sporadic colon cancers. Curr Opin Oncol 2009;21:369 –373. French AJ, Sargent DJ, Burgart LJ et al. Prognostic significance of defec- tive mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res 2008;14:3408 –3415. Jen J, Kim H, Piantadosi S et al. Allelic loss of chromosome 18q and prog- nosis in colorectal cancer. N Engl J Med 1994;331:213–221. Ogunbiyi OA, Goodfellow PJ, Herfarth K et al. Confirmation that chro- mosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol 1998;16:427– 433. Popat S, Houlston RS. A systematic review and meta-analysis of the re- lationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur J Cancer 2005;41:2060 –2070. Martínez-López E, Abad A, Font A et al. Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer. Gastroenterology 1998;114:1180 –1187. Popat S, Zhao D, Chen Z et al. Relationship between chromosome 18q status and colorectal cancer prognosis: A prospective, blinded analysis of 280 patients. Anticancer Res 2007;27:627– 633. Watanabe T, Wu TT, Catalano PJ et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001;344: 1196 –1206. Bertagnolli MM, Niedzwiecki D, Hall M et al. Presence of 18q loss of heterozygosity (LOH) and disease-free and overall survival in stage II co- lon cancer: CALGB Protocol 9581 [abstract 4012]. J Clin Oncol 2009; 27(15 suppl):171s. Benson AB 3rd. New approaches to assessing and treating early-stage co- lon and rectal cancers: Cooperative group strategies for assessing optimal approaches in early-stage disease. Clin Cancer Res 2007;13:6913s– 6920s. Tanaka T, Watanabe T, Kazama Y et al. Chromosome 18q deletion and Smad4 protein inactivation correlate with liver metastasis: A study matched for T- and N- classification. Br J Cancer 2006;95:1562–1567. Alazzouzi H, Alhopuro P, Salovaara R et al. SMAD4 as a prognostic marker in colorectal cancer. Clin Cancer Res 2005;11:2606 –2611. Alhopuro P, Alazzouzi H, Sammalkorpi H et al. SMAD4 levels and re- sponse to 5-fluorouracil in colorectal cancer. Clin Cancer Res 2005;11: 6311– 6316. Isaksson-Mettävainio M, Palmqvist R, Forssell J et al. SMAD4/DPC4 ex- pression and prognosis in human colorectal cancer. Anticancer Res 2006; 26:507–510. Gaasenbeek M, Howarth K, Rowan AJ et al. Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of het- erozygosity analysis reveals complex changes and multiple forms of chro- mosomal instability in colorectal cancers. Cancer Res 2006;66:3471– 3479. Trautmann K, Terdiman JP, French AJ et al. Chromosomal instability in microsatellite-unstable and stable colon cancer. Clin Cancer Res 2006;12: 6379 – 6385. Walther A, Houlston R, Tomlinson I. Association between chromosomal instability and prognosis in colorectal cancer: A meta-analysis. Gut 2008; 57:941–950. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307–310. 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 Biomarkers in Colon Cancer Adjuvant Treatment instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res 2001;7:1343–1349. Westra JL, Schaapveld M, Hollema H et al. Determination of TP53 mu- tation is more relevant than microsatellite instability status for the predic- tion of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol 2005;23:5635–5643. Petersen S, Thames HD, Nieder C et al. The results of colorectal cancer treatment by p53 status: Treatment-specific overview. Dis Colon Rectum 2001;44:322–333; discussion 333–334. Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: A systematic review. Br J Cancer 2005;92:434 – 444. Lenz HJ, Danenberg KD, Leichman CG et al. p53 and thymidylate syn- thase expression in untreated stage II colon cancer: Associations with re- currence, survival, and site. Clin Cancer Res 1998;4:1227–1234. Allegra CJ, Paik S, Colangelo LH et al. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes’ B and C colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 2003;21:241–250. Russo A, Bazan V, Iacopetta B et al. The TP53 colorectal cancer interna- tional collaborative study on the prognostic and predictive significance of p53 mutation: Influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 2005;23:7518 –7528. Popat S, Chen Z, Zhao D et al. A prospective, blinded analysis of thymi- dylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. Ann Oncol 2006;17:1810 –1817. Ahnen DJ, Feigl P, Quan G et al. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: A Southwest Oncology Group study. Cancer Res 1998;58:1149 –1158. Elsaleh H, Powell B, Soontrapornchai P et al. p53 gene mutation, micro- satellite instability and adjuvant chemotherapy: Impact on survival of 388 patients with Dukes’ C colon carcinoma. Oncology 2000;58:52–59. Lavin MF, Gueven N. The complexity of p53 stabilization and activation. Cell Death Differ 2006;13:941–950. Goh HS, Yao J, Smith DR. p53 point mutation and survival in colorectal cancer patients. Cancer Res 1995;55:5217–5221. Worthley DL, Whitehall VL, Spring KJ et al. Colorectal carcinogenesis: Road maps to cancer. World J Gastroenterol 2007;13:3784 –3791. Andreyev HJ, Norman AR, Cunningham D et al. Kirsten ras mutations in patients with colorectal cancer: The multicenter “RASCAL” study. J Natl Cancer Inst 1998;90:675– 684. Andreyev HJ, Norman AR, Cunningham D et al. Kirsten ras mutations in patients with colorectal cancer: The ‘RASCAL II’ study. Br J Cancer 2001;85:692– 696. Belly RT, Rosenblatt JD, Steinmann M et al. Detection of mutated K12- ras in histologically negative lymph nodes as an indicator of poor progno- sis in stage II colorectal cancer. Clin Colorectal Cancer 2001;1:110 –116. Roth AD, Tejpar S, Delorenzi M et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60 – 00 trial. J Clin Oncol 2010;28:466 – 474. Ogino S, Meyerhardt JA, Irahara N et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res 2009;15:7322–7329. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757–1765. Elsaleh H, Powell B, McCaul K et al. P53 alteration and microsatellite 80 Bouzourene H, Gervaz P, Cerottini JP et al. p53 and Ki-ras as prognostic